Propanc Biopharma, Inc. (PPCB) NASDAQ
0.11
+0.0131(+13.44%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.11
+0.0131(+13.44%)
Currency In USD
Address
302, 6 Butler Street
Camberwell, VIC 3124
Australia
Phone
61 3 9882 0780
Website
Sector
Healthcare
Industry
Biotechnology
Employees
1
First IPO Date
November 12, 2012
| Name | Title | Pay | Year Born |
| James Nathanielsz | Chief Executive Officer & Executive Chairman | 563,732 | 1974 |
| Klaus Kutz | Chief Medical Officer & Member of Scientific Advisory Board | 18,229 | N/A |
| Julian Norman Kenyon | Chief Scientific Officer & Director | 35,481 | 1948 |
| Jeannine Zimmerman | Chief Financial Officer | 0 | 1977 |
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.